<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876329</url>
  </required_header>
  <id_info>
    <org_study_id>FKE20130010H</org_study_id>
    <nct_id>NCT01876329</nct_id>
  </id_info>
  <brief_title>Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients</brief_title>
  <official_title>Presence of Autoantibodies to Gastric Parietal Cells and Subsequent Vitamin B12 Deficiency in Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keesler Air Force Base Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keesler Air Force Base Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A review of the literature reveals that very few studies have assessed the potential
      co-existence of vitamin B12 deficiency due to gastric parietal cell autoantibodies. While
      Segal et al. in 2004 published a study which found that 49% of patients with RA had vitamin
      B12 deficiency, no assessment of the etiology or the presence of autoantibodies was made.
      While Goeldner et al. in 2011 and Datta et al. in 1990 demonstrated that anti-gastric
      parietal cell antibodies (anti-GPC Ab) were found in &lt;5% to 28% of RA patients respectively,
      no additional testing was implemented to determine the significance, specifically whether or
      not the presence of anti-GPC Ab related to vitamin B12 deficiency.

      The purpose of this study is to determine the prevalence and metabolic significance of
      anti-GPC Ab in three cohorts: (1) a group of patients with Rheumatoid Arthritis, (2) a group
      of patients with autoimmune thyroid disease (AITD), and (3) a group of patients with neither
      RA or AITD. To determine the significance of the presence of anti-GPC Ab, testing of the
      current serum B12 level along with a metabolite dependent on adequate vitamin B12 levels
      (Methylmalonic acid) will be tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Organ specific antibodies such as anti-gastric parietal cell antibodies (anti-GPC
      Ab) have been found in a variable number of patients with RA, but it is unclear what
      significance these antibodies have on actual vitamin B12 levels. Patients with RA have been
      found to have vitamin B12 deficiency up to near 50% but it is unclear if this deficiency is
      due to anti-GPC Ab.

      Hypothesis: By virtue of the aberrant autoimmune process that occurs in RA, patients with RA
      are more likely to have anti-GPC Ab and more likely than a control arm or participants with
      autoimmune thyroid disease (AITD) to have vitamin B12 deficiency.

      Method: 135 patients will be consented; 45 to the RA arm, 45 to an AITD arm, and 45 to a
      control arm. Exclusion criteria will filter patients who would have other reasons for altered
      vitamin B12 absorption, such as inflammatory bowel disease, surgery, or medication use. After
      obtaining consent subjects will be sent to lab a serum anti-GPC Ab test (obtainable in an SLE
      panel), RF, B12/folate (as available for ordering in CHCS), methyl malonic acid, and (for the
      control arm subjects and AITD subjects) an anti-CCP IgG. Patients will also complete a
      one-sided, one page questionnaire asking them about dietary and medication exposures.

      Outcomes: (1) Determine whether evidence of serum vitamin B12 deficiency, as measure by
      either a low vitamin B12 level or elevated methylmalonic acid, will be more common in RA
      patients with anti-GPC Ab. (2) Determine the prevalence of anti-GPC Ab in a group of patients
      with RA as compared to a group of patients with AITD and with no known systemic or organ
      specific autoimmune condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Vitamin B12 Deficiency</measure>
    <time_frame>7 months</time_frame>
    <description>Hypothesis: Evidence of serum vitamin B12 deficiency, as measure by either a low vitamin B12 level or elevated methylmalonic acid, will be more common in RA patients with anti-GPC Ab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of Anti-GPC Antibodies</measure>
    <time_frame>7 months</time_frame>
    <description>Hypothesis: Evidence of anti-GPC Ab in a group of patients with RA will be more prevalent as compared to a group of patients with AITD and with no known systemic or organ specific autoimmune condition.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>Vitamin B12 Deficiency</condition>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
    <description>Patients with seropositive or seronegative Rheumatoid Arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autoimmune Thyroid Disease (AITD)</arm_group_label>
    <description>Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from the Internal Medicine and Internal Medicine Specialty
        Clinics at one academic community hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, age 18 and older

          -  RA arm: History of Rheumatoid Arthritis

          -  AITD arm: History of an autoimmune thyroid disease without a history or clinically
             obvious manifestation of an organ specific or systemic autoimmune process.

          -  Control arm: No history of RA and no history or clinically obvious manifestation of an
             organ specific or systemic autoimmune process.

        Exclusion Criteria:

          -  Known vitamin B12 deficiency for which the participant was formerly treated or
             continues to receive therapy.

          -  Active malabsorptive state to include but not limited to celiac disease, inflammatory
             bowel disease, etc.

          -  Surgically induced malabsorptive state to include but not limited to Roux-en-Y Gastric
             bypass

          -  Use of medications that may interfere with vitamin B12 absorption

          -  Patients with a thyroid condition not consistent with an autoantibody process (i.e.
             congenital absence of the thyroid, infectious thyroiditis, thyroidectomy for
             non-autoimmune process, toxic multinodular goiter) will be excluded from the
             autoimmune thyroid arm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew B Carroll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keesler Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keesler Medical Center</name>
      <address>
        <city>Keesler AFB</city>
        <state>Mississippi</state>
        <zip>39534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2013</study_first_submitted>
  <study_first_submitted_qc>June 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <results_first_submitted>April 9, 2015</results_first_submitted>
  <results_first_submitted_qc>May 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2015</results_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Keesler Air Force Base Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew B. Carroll, LtCol, USAF, MC, FACP, FACR</investigator_full_name>
    <investigator_title>Chief of Rheumatology</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Vitamin B12 deficiency</keyword>
  <keyword>Autoimmune Thyroid Disease</keyword>
  <keyword>Autoantibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Vitamin B 12 Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rheumatoid Arthritis</title>
          <description>Patients with seropositive or seronegative Rheumatoid Arthritis</description>
        </group>
        <group group_id="P2">
          <title>Autoimmune Thyroid Disease (AITD)</title>
          <description>Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rheumatoid Arthritis</title>
          <description>Patients with seropositive or seronegative Rheumatoid Arthritis</description>
        </group>
        <group group_id="B2">
          <title>Autoimmune Thyroid Disease (AITD)</title>
          <description>Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="13.1"/>
                    <measurement group_id="B2" value="55.1" spread="17.2"/>
                    <measurement group_id="B3" value="55.8" spread="16.4"/>
                    <measurement group_id="B4" value="56.8" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Vitamin B12 Deficiency</title>
        <description>Hypothesis: Evidence of serum vitamin B12 deficiency, as measure by either a low vitamin B12 level or elevated methylmalonic acid, will be more common in RA patients with anti-GPC Ab.</description>
        <time_frame>7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with seropositive or seronegative Rheumatoid Arthritis</description>
          </group>
          <group group_id="O2">
            <title>Autoimmune Thyroid Disease (AITD)</title>
            <description>Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Vitamin B12 Deficiency</title>
          <description>Hypothesis: Evidence of serum vitamin B12 deficiency, as measure by either a low vitamin B12 level or elevated methylmalonic acid, will be more common in RA patients with anti-GPC Ab.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Anti-GPC Antibodies</title>
        <description>Hypothesis: Evidence of anti-GPC Ab in a group of patients with RA will be more prevalent as compared to a group of patients with AITD and with no known systemic or organ specific autoimmune condition.</description>
        <time_frame>7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with seropositive or seronegative Rheumatoid Arthritis</description>
          </group>
          <group group_id="O2">
            <title>Autoimmune Thyroid Disease (AITD)</title>
            <description>Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Anti-GPC Antibodies</title>
          <description>Hypothesis: Evidence of anti-GPC Ab in a group of patients with RA will be more prevalent as compared to a group of patients with AITD and with no known systemic or organ specific autoimmune condition.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rheumatoid Arthritis</title>
          <description>Patients with seropositive or seronegative Rheumatoid Arthritis</description>
        </group>
        <group group_id="E2">
          <title>Autoimmune Thyroid Disease (AITD)</title>
          <description>Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew B. Carroll, MD</name_or_title>
      <organization>Keesler Medical Center</organization>
      <phone>228-376-3629</phone>
      <email>matthew.carroll.1@us.af.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

